Post by Secarna Pharmaceuticals

Secarna Pharmaceuticals and Protalix Biotherapeutics have entered into a collaboration and option agreement to jointly develop pharmaceutical candidates for rare renal indications.   This collaboration combines Secarna’s proven expertise in rapidly generating high-quality oligonucleotide candidates with Protalix’s deep know-how in advancing programs to patients worldwide.   Find out more details in our press release: https://lnkd.in/e-jHdVWa   #oligonucleotides #ASO #rarediseases